Page last updated: 2024-08-23

paroxetine and Hepatitis C, Chronic

paroxetine has been researched along with Hepatitis C, Chronic in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (80.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hou, XJ; Wang, J; Xu, JH; Yu, YY	1
Asnis, GM; De La Garza, R	1
Asnis, GM; Borisov, AS; Bruno, CJ; Demetrashvili, MF; Evans, DL; Henderson, MA; Miller, AH; Raison, CL; Reinus, JF; Staab, JP; Weinreib, R; Woolwine, BJ; Zajecka, JM	1
Kraus, MR; Schäfer, A; Scheurlen, M	1
Csef, H; Faller, H; Kraus, MR; Schäfer, A; Scheurlen, M	1

Reviews

2 review(s) available for paroxetine and Hepatitis C, Chronic

Article	Year
Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? PloS one, 2013, Volume: 8, Issue:10 Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Double-Blind Method; Hepatitis C, Chronic; Humans; Interferon-alpha; Paroxetine; Polyethylene Glycols; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome	2013
Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. Journal of clinical gastroenterology, 2006, Volume: 40, Issue:4 Topics: Anemia; Antiviral Agents; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon alpha-2; Interferon Type I; Interferon-alpha; Nitric Oxide; Paroxetine; Peptide Hydrolases; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors; Thyroid Diseases	2006

Article

Year

Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?

PloS one, 2013, Volume: 8, Issue:10

Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Double-Blind Method; Hepatitis C, Chronic; Humans; Interferon-alpha; Paroxetine; Polyethylene Glycols; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

2013

Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches.

Journal of clinical gastroenterology, 2006, Volume: 40, Issue:4

Topics: Anemia; Antiviral Agents; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon alpha-2; Interferon Type I; Interferon-alpha; Nitric Oxide; Paroxetine; Peptide Hydrolases; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors; Thyroid Diseases

2006

Trials

1 trial(s) available for paroxetine and Hepatitis C, Chronic

Article	Year
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary pharmacology & therapeutics, 2007, May-15, Volume: 25, Issue:10 Topics: Adolescent; Adult; Aged; Antiviral Agents; Depressive Disorder, Major; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Paroxetine; Ribavirin	2007

Other Studies

2 other study(ies) available for paroxetine and Hepatitis C, Chronic

Article	Year
Paroxetine for the prevention of depression induced by interferon alfa. The New England journal of medicine, 2001, Aug-02, Volume: 345, Issue:5 Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Depressive Disorder; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Paroxetine; Recombinant Proteins	2001
Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:6 Topics: Adolescent; Adult; Aged; Antiviral Agents; Depressive Disorder; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Paroxetine; Patient Compliance; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome	2002

Article

Year

Paroxetine for the prevention of depression induced by interferon alfa.

The New England journal of medicine, 2001, Aug-02, Volume: 345, Issue:5

Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Depressive Disorder; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Paroxetine; Recombinant Proteins

2001

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:6

Topics: Adolescent; Adult; Aged; Antiviral Agents; Depressive Disorder; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Paroxetine; Patient Compliance; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome

2002